Showing 6811-6820 of 9762 results for "".
- Health Canada Clears Cutera’s AviClearhttps://practicaldermatology.com/news/health-canada-clears-cuteras-aviclear/2461268/Health Canada has cleared Cutera, Inc.’s AviClear for the treatment of mild, moderate, and severe acne. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, in March 2022. In addition
- Aveeno Names Winners of the 2022 Skin Health Accelerator Startup Pitch Competitionhttps://practicaldermatology.com/news/aveeno-names-winners-of-the-2022-skin-health-accelerator-startup-pitch-competition/2461263/Aveeno awarded the winners of the second installment of the brand’s
- Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI-100https://practicaldermatology.com/news/aditxt-inc-successfully-completes-preclinical-toxicity-study-of-its-psoriasis-drug-candidate-adi-100/2461260/Aditxt, Inc.’s
- Study: Colorescience’s All Calm Regimen Reduces Redness, Inflammationhttps://practicaldermatology.com/news/study-coloresciences-all-calm-regimen-reduces-redness-inflammation/2461253/Colorescience’s All Calm Regimen calms inflammation and reduces redness, according to a new study in the Journal of Cosmetic Dermatology. The 12-week study consisted of two subject groups. Group A subjec
- Study: Females Itch Less than Maleshttps://practicaldermatology.com/news/study-females-itch-less-than-males/2461252/Females have a significantly lower incidence of severe psoriasis, however, the underlying reason for the sex differences has remained unclear. Now, a team of researchers has found that the female hormone estradiol suppresses psoriasis, and the protective role of the hormone ha
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- New Crystal Ball Predictions Released by Allergan Aestheticshttps://practicaldermatology.com/news/new-crystal-ball-predictions-released-by-allergan-aesthetics/2461238/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- Vial Dermatology CRO adds Dr. Jonathan Zung to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-dermatology-cro-adds-dr-jonathan-zung-to-scientific-advisory-boar/2461236/The Vial Dermatology CRO welcomed Jonathan Zung, PhD, as the newest addition to the Vial Scientific Advisory Board. Dr. Zung will support the Vial CRO team and their sponsors to further advance the field of dermatology clinical researc
- FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis/2461224/The FDA has approved Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab) for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regu
- June 2022 Marks Scleroderma Awareness Monthhttps://practicaldermatology.com/news/june-2022-marks-scleroderma-awareness-month/2461222/June is Scleroderma Awareness Month, and "Know Scleroderma" is the National Scleroderma Foundation's theme for 2022. Throughout the month, the Foundation will post videos and photos of individuals affected by scleroderma on its